SANDOZ WAKES: CIBA MERGER GIVES COMPANY FOCUS THROUGH END OF DECADE; NOVARTIS WILL BE 8TH LARGEST U.S. FIRM, LOOKING FOR $1.5 BIL. IN SAVINGS WORLDWIDE
The Sandoz/Ciba merger will give Sandoz a clearly defined mission through the end of the decade after several years of strategic uncertainty: to wring cost-savings and synergies out of the $27 bil. Novartis transaction.
You may also be interested in...
Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011